A new multi-institution study spearheaded by researchers at Florida State University and the University of California, Los Angeles suggests a tiny protein could play a major role in combating heart failure related to Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder among children.
In collaboration with scientists from across the nation, FSU researchers found that increased levels of the protein sarcospan improve cardiac function by reinforcing cardiac cell membranes, which become feeble in patients with DMD.
Their findings were published in the journal JCI Insight.
The condition, which typically afflicts young boys, is caused by a mutation that prevents the body from producing dystrophin, a protein crucial to the health of skeletal, respiratory and cardiac muscles. Advances in treatment for certain types of DMD-related muscle degradation have helped to prolong patients’ lifespans. However, as DMD patients age, their heart function declines dramatically.
“Patients typically live to 20 or 30 years of age,” said lead author Michelle Parvatiyar, an assistant professor in the Department of Nutrition, Food and Exercise Sciences in FSU’s College of Human Sciences. “There have been important improvements in respiratory care, which used to be what a majority of patients would succumb to. Now, in their 20s and 30s, they’re often succumbing to cardiomyopathy. The heart is functioning with a major component of the cell membrane missing. Over time, it wears out.”
The study was part of continued efforts by UCLA biologist Rachelle H. Crosbie, the study’s corresponding author, who previously identified sarcospan as a protein that could improve mechanical support in skeletal cell membranes lacking dystrophin. Her finding buoyed DMD researchers and affirmed sarcospan’s potential as an effective tool in the fight against the condition.
“But nobody had really looked at how increasing the levels of this protein might affect the heart,” Parvatiyar said.
Using a unique mouse model with a dearth of dystrophin, Parvatiyar and her collaborators did just that.
In their study, the team found that while it’s is not a like-for-like replacement for dystrophin, an overexpression of sarcospan in cardiac cells seems to do the job of stabilizing cell membranes. Even under stress, researchers found, sarcospan overexpression was able to improve the membrane defect in dystrophin-deficient cells.
“Sarcospan doesn’t quite do the job of dystrophin, but it acts as a glue to stabilize the membrane and hold protein complexes together when dystrophin is lacking,” said Parvatiyar, explaining a concept developed by Crosbie.
Cardiac measurements confirmed that sarcospan does protect the cell membrane even when the heart is placed under stress. Study co-author and FSU College of Medicine Associate Professor Jose Pinto performed the measurements, along with FSU graduate student Karissa Dieseldorff Jones and University of Miami Miller School of Medicine research assistant Rosemeire Takeuchi Kanashiro.
In addition to serving as a kind of stabilizing glue, researchers said sarcospan could also act as a scaffold that supports other essential proteins at the cell membrane. That function could allow sarcospan to carry mini versions of dystrophin — which, in its normal state, has a long and unwieldy genetic code — to the edges of cardiac cells, where they could buttress the fragile membranes.
“The idea is that you could administer the sarcospan and the dystrophin at the same time, and the sarcospan could facilitate mini dystrophin localizing to the cell membrane and help hold those complexes in place,” Parvatiyar said.
Sarcospan’s two possible functions could augment existing DMD treatments, Parvatiyar said, or they could give rise to novel therapies that fortify weakened cardiac cell membranes and improve the quality of life for people with DMD.
In her previous position at UCLA, Parvatiyar had frequent interactions with DMD patients and their families. She said these interactions, and the unshakeable hope she’s witnessed in those suffering from DMD, continue to drive her and her colleagues in the search for new ways to combat this debilitating condition.
“Those were the first times in my life I’d ever had someone come up to me and thank me for my work,” she said. “Sometimes you can feel removed from it in the laboratory day after day. You see incremental progress. But to see people who are really yearning for help is motivating. Their positivity is incredibly inspiring.”
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Duchenne Muscular Dystrophy Treatment Market Outlook 2025, Size, Forecasts, Demand, Competitive Analysis, Growth Factors, Key Playerson January 19, 2021 at 11:18 pm
The propelling factors for the growth of the Duchenne muscular dystrophy (DMD) treatment market include the rising disease burden of Duchenne muscular dystrophy, increasing investments in ...
- Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technologyon January 19, 2021 at 9:35 am
PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced a $1 million programmatic investment ...
- You Searched For "duchenne muscular dystrophy"on January 17, 2021 at 6:03 am
Get Latest News, Breaking News about duchenne muscular dystrophy. Stay connected to all updated on duchenne muscular dystrophy ...
- Cureduchenne Launches Initiative To Prioritize Duchenne Community Needs For COVID-19 Vaccine Rollouton January 14, 2021 at 4:01 pm
CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a new initiative centered on the COVID-19 vaccine rollout and Duchenne ...
- Duchenne Muscular Dystrophy Drugs Market 2021 Share, Size Global Growth Analysis, Trends, Industry Analysis, Key Players and Forecast to 2025on January 12, 2021 at 6:38 am
Global Duchenne Muscular Dystrophy Drugs Market Research Report focuses on market size, status and forecast 2020-2025, along with this report also focuses on market opportunities and treats, risk ...
- CureDuchenne Congratulates Pfizer on Dosing First Patient in Phase III Clinical Trial for Duchenne Muscular Dystrophyon January 8, 2021 at 2:57 pm
CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), celebrates Pfizer Inc’s (NYSE: ...
- Sarepta Stock Plunges on Mixed Muscular Dystrophy Resultson January 8, 2021 at 9:27 am
Sarepta Therapeutics announced topline results from Part 1 of Study SRP-9001-102 for the company's investigational gene transfer therapy for Duchenne muscular dystrophy (DMD).
- Duchenne-focused biotech Sarepta loses $6.5B in value after trial failon January 8, 2021 at 4:03 am
Shares of Sarepta Therapeutics Inc., which employs more than 600 people in Massachusetts, were cut in half in after-hours trading Thursday night after a highly anticipated gene therapy for Duchenne ...
- Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcomeon January 7, 2021 at 1:50 pm
The study failed to produce statistically significant improvements in muscle function for all patients after one year.
- Parent Project Muscular Dystrophy Announces 2021 Certified Duchenne Care Center Inter-Institutional Collaboration Grant Programon January 7, 2021 at 7:00 am
PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) is ...
via Bing News